Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.

Abstract excerpt

Lung malignant tumors are a type of cancer with high incidence and mortality rates worldwide. Non-small cell lung cancer (NSCLC) accounts for over 80% of all lung malignant tumors, and most patients are diagnosed at advanced stages, leading to poor prognosis. Over the past decades, various oncogenic driver alterations associated with lung cancer have been identified, each of which can potentially serve as a...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• KRAS gene
• Lung Neoplasms
• Molecular Targeted Therapy
• Mutation